Urea Cycle Disorders Clinical Trial
Official title:
Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders
The primary purpose of the proposed study is to characterize the oxidative stress and inflammatory cytokine status in UCD during baseline and decompensated states.
Protein turnover is a cyclic process with a net loss of protein in the fasting state and a
net gain in the fed state contributing to nitrogen balance. These physiologic processes are
impacted during infection; whole-body protein catabolism exceeds protein synthesis,
resulting in net loss of whole-body protein. Patients with urea cycle disorders suffer
episodes of periodic hyperammonemic crisis, often in association with intercurrent
infections. The immediate cause of this decompensation is the increase in endogenous protein
catabolism that is the endpoint of a cascade triggered by intercurrent illness. This
increase in protein catabolism leads to elevations of serum amino acids and ammonia
production, which cannot be eliminated by a dysfunctional urea cycle.
It is well known that infectious illnesses play a significant role in precipitating
metabolic crises in urea cycle defects, presumably by triggering a cascade of events
involving the release of inflammatory cytokines that lead to increased protein catabolism.
Cytokines have also been implicated as distant mediators of oxidative stress. However, the
correlation between oxidative stress, cytokine levels, and severity of a crisis is currently
unclear.
The primary purpose of the proposed study is to characterize the oxidative stress and
inflammatory cytokine status in UCD during baseline and decompensated states. The
investigators will undertake measurements of selected markers of oxidative stress and
cytokines in serum and urine during baseline and decompensated states in subjects with UCD
in order to establish their prognostic value as biomarkers for disease severity and/or
predictors of metabolic decompensation.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02252770 -
Nitric Oxide Supplementation in Argininosuccinic Aciduria
|
N/A | |
Completed |
NCT01002469 -
Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment
|
N/A | |
Completed |
NCT00986895 -
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
|
Phase 1 | |
Completed |
NCT01257737 -
To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)
|
Phase 4 | |
Recruiting |
NCT05671666 -
Ureagenesis Analysis in Healthy Subjects and in Urea Cycle Disorder Patients
|
N/A | |
Completed |
NCT02311283 -
Pilot Study: Urea Cycle Disorders Practice Patterns and Outcomes Assessment
|
N/A | |
Completed |
NCT02489292 -
Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002)
|
Phase 2 | |
Completed |
NCT00992459 -
Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders
|
Phase 3 | |
Completed |
NCT00551200 -
Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders
|
Phase 2 | |
Completed |
NCT00947297 -
Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
|
Phase 3 | |
Completed |
NCT02740153 -
PCORI Urea Cycle Disorder Study
|
||
Completed |
NCT02051049 -
Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)
|
||
Completed |
NCT01765283 -
Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)
|
Phase 1/Phase 2 | |
Completed |
NCT00947544 -
Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders
|
Phase 2 | |
Completed |
NCT01347073 -
Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)
|
Phase 3 | |
Completed |
NCT00718627 -
Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders
|
Phase 2 | |
Completed |
NCT03797131 -
Clinical Food Study to Evaluate the Effect of KB195 on Gut Nitrogen Metabolism in Patients With Urea Cycle Disorders
|
N/A | |
Completed |
NCT01549015 -
Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function
|
N/A | |
Completed |
NCT00345605 -
Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder
|
Phase 2 | |
Recruiting |
NCT00237315 -
Longitudinal Study of Urea Cycle Disorders
|